$10.74
0.030.28%
At Close: -
$11.25
0.514.75%
After Hours: Jul 19, 6:22 PM EDT
15 minutes delayed
Comments
Loading...
IGM Biosciences
IGMSNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
IGM Biosciences (NASDAQ:IGMS) Stock, Analyst Ratings, Price Targets, Forecasts
IGM Biosciences Inc has a consensus price target of $31.67 based on the ratings of 13 analysts. The high is $126 issued by Jefferies on December 13, 2021. The low is $8 issued by B of A Securities on December 15, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Wedbush, and HC Wainwright & Co. on May 24, 2024, May 9, 2024, and April 18, 2024, respectively. With an average price target of $14.67 between HC Wainwright & Co., Wedbush, and HC Wainwright & Co., there's an implied 30.37% upside for IGM Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
RBC Capital
B of A Securities
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for IGM Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/24/2024 | Buy Now | 6.67% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 77.78% | Wedbush | Robert Driscoll | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 04/18/2024 | Buy Now | 6.67% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 03/12/2024 | Buy Now | 6.67% | HC Wainwright & Co. | Robert Burns | $7 → $12 | Maintains | Neutral | Get Alert |
| 03/08/2024 | Buy Now | 86.67% | RBC Capital | Brian Abrahams | → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 77.78% | Wedbush | Robert Driscoll | → $20 | Reiterates | Outperform → Outperform | Get Alert |
| 02/09/2024 | Buy Now | 86.67% | RBC Capital | Brian Abrahams | $9 → $21 | Upgrade | Sector Perform → Outperform | Get Alert |
| 12/15/2023 | Buy Now | -28.89% | B of A Securities | Geoff Meacham | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 12/07/2023 | Buy Now | -37.78% | HC Wainwright & Co. | Robert Burns | $11 → $7 | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2023 | Buy Now | -20% | RBC Capital | Brian Abrahams | $8 → $9 | Maintains | Sector Perform | Get Alert |
| 11/15/2023 | Buy Now | -28.89% | Morgan Stanley | Michael Lapides | $15 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | -2.22% | HC Wainwright & Co. | Robert Burns | $17 → $11 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 122.22% | Stifel | Stephen Willey | $26 → $25 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | -28.89% | RBC Capital | Brian Abrahams | $11 → $8 | Maintains | Sector Perform | Get Alert |
| 09/06/2023 | Buy Now | 122.22% | Truist Securities | Asthika Goonewardene | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/17/2023 | Buy Now | -2.22% | RBC Capital | Brian Abrahams | → $11 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/07/2023 | Buy Now | — | Needham | Matt McGinley | — | Downgrade | Buy → Hold | Get Alert |
| 08/07/2023 | Buy Now | 51.11% | HC Wainwright & Co. | Robert Burns | $22 → $17 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | 33.33% | Morgan Stanley | Michael Lapides | $20 → $15 | Maintains | Equal-Weight | Get Alert |
| 06/06/2023 | Buy Now | 95.56% | HC Wainwright & Co. | Robert Burns | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2023 | Buy Now | 228.89% | Wedbush | Robert Driscoll | → $37 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | 68.89% | JP Morgan | Eric Joseph | $26 → $19 | Maintains | Neutral | Get Alert |
| 05/15/2023 | Buy Now | 228.89% | Wedbush | Robert Driscoll | $41 → $37 | Maintains | Outperform | Get Alert |
| 05/15/2023 | Buy Now | 51.11% | RBC Capital | Brian Abrahams | $21 → $17 | Maintains | Sector Perform | Get Alert |
| 04/04/2023 | Buy Now | 122.22% | Truist Securities | Asthika Goonewardene | $37 → $25 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 131.11% | JP Morgan | Eric Joseph | $27 → $26 | Maintains | Neutral | Get Alert |
| 04/03/2023 | Buy Now | 77.78% | Morgan Stanley | Michael Lapides | $30 → $20 | Maintains | Equal-Weight | Get Alert |
| 04/03/2023 | Buy Now | 95.56% | HC Wainwright & Co. | Robert Burns | $45 → $22 | Maintains | Buy | Get Alert |
| 03/31/2023 | Buy Now | 86.67% | RBC Capital | Brian Abrahams | $24 → $21 | Maintains | Sector Perform | Get Alert |
| 11/09/2022 | Buy Now | 388.89% | Jefferies | Roger Song | $61 → $55 | Assumes | → Buy | Get Alert |
| 11/07/2022 | Buy Now | 300% | HC Wainwright & Co. | Robert Burns | $58 → $45 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 95.56% | RBC Capital | Brian Abrahams | $27 → $22 | Maintains | Sector Perform | Get Alert |
| 10/17/2022 | Buy Now | 140% | JP Morgan | Eric Joseph | → $27 | Initiates | → Neutral | Get Alert |
| 08/29/2022 | Buy Now | 202.22% | B of A Securities | Geoff Meacham | → $34 | Initiates | → Buy | Get Alert |
| 08/23/2022 | Buy Now | 228.89% | Truist Securities | Asthika Goonewardene | $74 → $37 | Maintains | Buy | Get Alert |
| 06/01/2022 | Buy Now | 175.56% | Baird | Joel Beatty | $46 → $31 | Maintains | Outperform | Get Alert |
| 05/17/2022 | Buy Now | 415.56% | HC Wainwright & Co. | Robert Burns | $59 → $58 | Maintains | Buy | Get Alert |
| 04/04/2022 | Buy Now | 308.89% | Baird | Joel Beatty | $65 → $46 | Maintains | Outperform | Get Alert |
| 03/31/2022 | Buy Now | 424.44% | HC Wainwright & Co. | Robert Burns | $76 → $59 | Maintains | Buy | Get Alert |
| 03/30/2022 | Buy Now | 557.78% | Truist Securities | Asthika Goonewardene | $80 → $74 | Maintains | Buy | Get Alert |
| 03/30/2022 | Buy Now | 166.67% | Morgan Stanley | Michael Ulz | $25 → $30 | Maintains | Equal-Weight | Get Alert |
| 12/16/2021 | Buy Now | 575.56% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 12/14/2021 | Buy Now | 237.78% | Morgan Stanley | Michael Ulz | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/13/2021 | Buy Now | 477.78% | Stifel | Stephen Willey | — | Maintains | Buy | Get Alert |
| 12/13/2021 | Buy Now | 1020% | Jefferies | Chris Howerton | — | Maintains | Buy | Get Alert |
| 12/13/2021 | Buy Now | 353.33% | RBC Capital | Brian Abrahams | — | Downgrade | Outperform → Sector Perform | Get Alert |
| 11/05/2021 | Buy Now | 700% | RBC Capital | Brian Abrahams | — | Maintains | Outperform | Get Alert |
| 11/05/2021 | Buy Now | 628.89% | Wedbush | Robert Driscoll | — | Upgrade | Neutral → Outperform | Get Alert |
| 08/26/2021 | Buy Now | 788.89% | Morgan Stanley | Michael Ulz | — | Initiates | → Overweight | Get Alert |
| 08/16/2021 | Buy Now | 628.89% | Wedbush | Robert Driscoll | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for IGM Biosciences (IGMS) stock?
The latest price target for IGM Biosciences (NASDAQ:IGMS) was reported by HC Wainwright & Co. on May 24, 2024. The analyst firm set a price target for $12.00 expecting IGMS to rise to within 12 months (a possible 6.67% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IGM Biosciences (IGMS)?
The latest analyst rating for IGM Biosciences (NASDAQ:IGMS) was provided by HC Wainwright & Co., and IGM Biosciences reiterated their neutral rating.
When was the last upgrade for IGM Biosciences (IGMS)?
The last upgrade for IGM Biosciences Inc happened on February 9, 2024 when RBC Capital raised their price target to $21. RBC Capital previously had a sector perform for IGM Biosciences Inc.
When was the last downgrade for IGM Biosciences (IGMS)?
The last downgrade for IGM Biosciences Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $8 for IGM Biosciences Inc.
When is the next analyst rating going to be posted or updated for IGM Biosciences (IGMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on May 24, 2024 so you should expect the next rating to be made available sometime around May 24, 2025.
Is the Analyst Rating IGM Biosciences (IGMS) correct?
While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a reiterated with a price target of $12.00 to $12.00. The current price IGM Biosciences (IGMS) is trading at is $11.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.